Develops precision small-molecule inhibitors targeting FGFR genetic alterations in cancer and genetic skeletal disorders.
Develops precision small-molecule inhibitors targeting FGFR genetic alterations in cancer and genetic skeletal disorders.
Has no product on the market, so no sales; it is funded by money raised from investors and spends it on clinical trials of its FGFR drugs. Its approach is to design drugs that keep working when cancer cells mutate to resist older ones. It went public in 2023.
Moat: none (IP / patents, process know-how). Proprietary structure-based platform designs FGFR inhibitors resistant to resistance mutations, but is clinical-stage.
Headquarters: Carlsbad, California, US · Founded: 2018 · Employees: 87
Size Tyra Bioscience (TYRA) is a United States Health Care company (Biotechnology) with a market value of $1.35B, the 2040th largest of 3,085 United States companies the cockpit tracks. Shares closed at $19.61 on 18 Nov 2026.
Performance Over six months the shares fell 41.3%, against -20.3% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 20 in its peer set.
Short interest Short interest is 14.3% of the free float (30 Oct 2026).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$538,000 | -$546,000 | -$519,000 | -$353,000 | -$296,000 |
| EBITDA | -$182M | -$132M | -$104M | -$79.6M | -$58.6M |
| Net income | -$170M | -$120M | -$86.5M | -$69.1M | -$55.3M |
| Free cash flow | -$120M | -$95.3M | -$70.4M | -$50.9M | -$50.8M |
| Capital expenditure | $301,000 | $141,000 | $664,000 | $770,000 | $559,000 |
| Total debt | $5.46M | $5.81M | $6.22M | $6.50M | $2.62M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Tyra Bioscience TYRA | $1.35B | -41% | n/a | n/a | n/a | n/a |
| BridgeBio Pharma BBIO | $15.2B | +14% | +167% | -37% | 19.1× | n/a |
| Incyte INCY | $24.0B | +21% | +25% | 12% | 3.4× | 14.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TYRA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.2% | -15.3% | 6th highest of 21 |
| 6-month return | -41.3% | -20.3% | 2nd lowest of 20 |
| Distance from 52-week high | -51.8% | -47.0% | 7th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tyra Bioscience TYRA | United States | $1.35B | -41% | n/a | n/a | n/a | n/a | n/a |
| CanSino Biologics 6185.HK | Hong Kong | $1.36B | -23% | +36% | -4% | 6.8× | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.34B | -20% | +56% | -737% | 31.7× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | 21.3× | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.34B | -16% | +654% | -61% | 5.7× | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | 408.9× | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | 50.1× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.32B | n/a | +238% | -1,196% | 164.8× | n/a | n/a |
| Novavax NVAX | United States | $1.31B | -14% | -61% | -17% | 2.4× | n/a | n/a |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 7.9× | 0.5% | +25.6% |
| Taysha Gene Therapies TSHA | United States | $1.30B | -27% | -13% | -2,998% | 170.1× | n/a | n/a |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | 835.7× | n/a | n/a |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | 65.4× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 4.9× | 39.4% | -2.5% |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | 2.3× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | 205.0× | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 6.3× | n/a | n/a |
| Hualan Biological Vaccine 301207.SZ | China | $1.25B | -29% | -28% | -7% | 9.0× | 33.2% | -13.1% |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | n/a | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.24B | -21% | +1% | 10% | 3.5× | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | 12.8× | n/a | n/a |